EA Schongau is threatened with relegation: can the team cope with the pressure?

EA Schongau is threatened with relegation: can the team cope with the pressure?

It's not easy in sport - especially when the start of the season doesn't go according to plan. EA Schongau has struggled with one win from five games this season and could find itself in the bottom of the table. After a hoped-for 7:3 win against Burgau, the team had to accept a bitter 1:4 defeat against the Peißenberg Miners, which clearly shows the problems in the team. Coach Christian Kratzmeir gave vent to his disappointment in the derby and we can only hope that his boys can turn things around in the upcoming home game against the Donau Devils Ulm/Neu-Ulm on Friday at 8 p.m. Another duel is scheduled for Sunday, this time against the pointless EC Pfaffenhofen at 5:30 p.m.

It remains to be seen whether the team around Lukas Skvarek, who has scored one goal in four games so far, can stabilize. The questions that concern fans are not just of a sporting nature. There are also a few things happening in the medical field that could be important for many people.

New advances in the treatment of ulcerative colitis

Research into drugs for ulcerative colitis and Crohn's disease has made enormous progress in recent years. Chronic inflammatory bowel disease is no longer uncommon these days and a complete cure remains a long way off. But there is light at the end of the tunnel. For example, mirikizumab (Omvoh®), an IL-23 inhibitor that showed promise in the Phase III LUCENT-2 trial, was approved in the EU in May 2023. Over 50 percent of participating patients achieved sustained remission over one year.

But risankizumab (Skyrizi®), which was approved in the EU at the end of July 2024, also shows good results. Here, 20 percent of patients achieved remission after twelve weeks. The most common side effects include upper respiratory tract infections and joint problems. The oral active ingredient etrasimod (Velsipity®) is also receiving attention, which was approved at the beginning of 2024 and in clinical tests already found 26 percent of patients symptom-free after three months.

Medical support for serious illnesses

It is particularly important for those affected to receive comprehensive information before taking new medications such as ENTYVIO® (vedolizumab). This medication is used to treat moderately to severely active ulcerative colitis and Crohn's disease. However, before starting treatment, all medical conditions should be discussed to rule out possible risks, such as severe allergic reactions or infections. Here too, proper advice from healthcare providers is essential.

The interface between sport and health needs more attention. While the Schongau hockey players concentrate on their performance, medicine offers those affected hope with new therapies. The developments in the medical field are significant and could play a big role for many people in the future. Whether in sports or medicine – challenges and opportunities await at every corner.